MapLight Therapeutics, Inc. Common Stock Market Cap ($295.95 Million)
Market Cap & Net Worth: MapLight Therapeutics, Inc. Common Stock (MPLT)
MapLight Therapeutics, Inc. Common Stock market cap. MapLight Therapeutics, Inc. Common Stock (NASDAQ:MPLT) has a market capitalization of $295.95 Million ($295.95 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14618 globally and #3487 in its home market, demonstrating a -14.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MapLight Therapeutics, Inc. Common Stock's stock price $6.78 by its total outstanding shares 43650321 (43.65 Million). Also see MPLT cash flow conversion for how efficiently the company converts equity into cash flow.
MapLight Therapeutics, Inc. Common Stock Market Cap History (2025–2026)
MapLight Therapeutics, Inc. Common Stock market cap history from 2025 to 2026. Data shows growth from $766.72 Million to $295.95 Million (0.00% CAGR). Check MPLT stock price and chart for real-time trading data and today's change.
MapLight Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MapLight Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MapLight Therapeutics, Inc. Common Stock annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MPLT by Market Capitalization
Companies near MapLight Therapeutics, Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see MapLight Therapeutics, Inc. Common Stock total assets for a full breakdown of the balance sheet.
Key companies related to MapLight Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of MapLight Therapeutics, Inc. Common Stock (2025–2026)
Market capitalization of MapLight Therapeutics, Inc. Common Stock from 2025 to today. Between 2025 and today, MapLight Therapeutics, Inc. Common Stock's market cap moved from $766.72 Million to $ 295.95 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $295.95 Million | -61.40% |
| 2025 | $766.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of MapLight Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $295.95 Million USD |
| MoneyControl | $295.95 Million USD |
| MarketWatch | $295.95 Million USD |
| marketcap.company | $295.95 Million USD |
| Reuters | $295.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more